CagriSema (cagrilintide + semaglutide) hits 22.7% weight loss in REDEFINE 1, NEJM reports

The amylin/GLP-1 combination CagriSema - Novo Nordisk's cagrilintide paired with semaglutide - achieved 22.7% mean weight loss at 68 weeks in the phase 3a REDEFINE 1 trial in adults with overweight or obesity, published in the New England Journal of Medicine (Davies et al., 2025). Roughly 40% of CagriSema-treated participants lost at least 25% of body weight, and the combination beat both semaglutide and cagrilintide alone. In REDEFINE 2 (type 2 diabetes) the regimen delivered up to a 1.91 percentage-point HbA1c reduction. A head-to-head (REDEFINE 4) showed CagriSema (23.0%) slightly trailing tirzepatide (25.5%), clarifying the competitive ordering at the top of the obesity market.